By Fineline Cube 
Shanghai Wankexin Biotechnology Partnership Enterprise (Limited Partnership) (“Wankexin Biotech”), a subsidiary of the Shanghai Biomedicine M&A Fund, will acquire China-based Chengdu Kanghua Biological Products Co. Ltd. (“Kanghua Biological”, SHE: 300841) through an agreement.
Acquisition Details
According to the announcement by Kanghua Biological, Wankexin Biotech intends to acquire 28,466,638 shares of Kanghua Biological. This represents 21.9064% of the total share capital after excluding shares held in the repurchase account. The transaction consideration is up to RMB 1.851 billion. Upon completion of the transaction, Wankexin Biotech will hold 29.9893% of the voting rights and become the controlling shareholder of Kanghua Biological.-Fineline Info & Tech